A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
This study will find the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and recommended Phase 2 dose (RPTD) of MK4827 when administered in combination with standard doses of carboplatin, or carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin in the treatment of advanced solid cancers in adults.
Cancer: Solid Tumors
DRUG: MK-4827|DRUG: carboplatin|DRUG: paclitaxel|DRUG: liposomal doxorubicin
Number of participants with dose limiting toxicities (DLTs), Each cycle (21 or 28 Days)
Number of participants with clinical and laboratory adverse events (AEs), Baseline to 30 days post last dose
The decision to discontinue new enrollment is not related to any concerns about the safety profile of the product.